LUNG CANCER

Significant improvements in progression-free survival were seen with sotorasib compared with docetaxel in patients with KRAS G12C–mutated non–small cell lung cancer.

Trastuzumab deruxtecan at 5.4mg/kg demonstrated clinically meaningful benefit in patients with HER2-mutated non–small cell lung cancer.

Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small cell lung cancer versus placebo, nor did subgroup analyses show statistically significant differences in DFS, according to results from the phase 3 CANOPY-A trial presented at ESMO Congress 2022.

Updated findings from the phase 3 ADAURA trial showed a significant disease-free survival improvement with the use of adjuvant osimertinib compared with placebo in patients with EGFR-mutated, stage I to IIIA non–small cell lung cancer.

Chemotherapy added to 1500 mg of MEDI5752, a PD-1/CTLA-4 bispecific monoclonal antibody, led to a doubling in duration of response compared with pembrolizumab and chemotherapy in patients with treatment-naïve nonsquamous non–small cell lung cancer.

Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study of adjuvant canakinumab for the treatment of patients with completely resected non-small cell lung cancer.

Adding a limited course of tremelimumab to durvalumab plus chemotherapy induced long-term OS in patients with metastatic NSCLC, even when stratified by histology and mutation status.

A study of air pollutant particulate matter shows that it may be a mechanistic driver for lung cancer, showing a need to curb its source.

The phase 2 NEOpredict trial of nivolumab with or without relatilmab met its primary end point of feasibility of treatment in patients with resectable non–small cell lung cancer.

In the first interview of this series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale of tumor-infiltrating lymphocytes and considers their potential use in the management of solid tumors.

Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.

In an interview with Targeted Oncology, Melina Elpi Marmarelis, MD, further discussed the findings revealed from the LACP cohort of the CHRYSALIS-2 study in non–small cell lung cancer.

During a live virtual event, Benjamin P. Levy, MD, discussed the case of a patient with non–small cell lung cancer and an EGFR exon 19 deletion. This is the second of two articles based on this event.

Top-line data from the SELECT trial of vopratelimab plus pimivalimab vs pimivalimab alone missed its primary end point of mean tumor change but showed encouraging trends for secondary end points.

Karen L. Reckamp, MD, discusses the key findings of the phase 2 Lung-MAP substudy S1800A for patients with stage IV, previously-treated non–small cell lung cancer.

The novel targeted therapy abivertinib showed efficacy in a clinical trial of patients with EGFR T790M mutations who previously received an EGFR inhibitor.

CE label expansion has been given to the VENTANA PD-L1 assay for patients with non-small cell lung cancer as a companion diagnostic for atezolizumab.

Brandon Sheffield, MD, explains the biomarkers that are important to identify before treating a patient who has been diagnosed with non–small cell lung cancer.

New findings suggest that all patients with lung cancer undergo germline testing.

The phase CANOPY-A study has missed its primary end point of disease-free survival improvement in patients with stages II to IIIA and IIIB completely resected non-small cell lung cancer.

Accelerated approval has been granted to trastuzumab deruxtecan for patients with HER2-positive unresectable or metastatic non-small cell lung cancer based on positive results from DESTINY-Lung02.

Survival outcomes of avelumab in patients with PD-L1-positive non-small cell lung cancer showed numeric improvement compared with chemotherapy, but missed the significance threshold in the JAVELIN Lung 100 study.

An easy way to double survival for patients with lung cancer is by removing the barriers to screening.

Datopotamab deruxtecan and pembrolizumab with or without platinum-based chemotherapy showed promising efficacy and a manageable safety profile in advanced/metastatic non–small cell lung cancer without actionable genomic alterations.

Pembrolizumab and etoposide continues to demonstrate improvements in survival outcomes compared with placebo and etoposide in patients with previously untreated extensive stage-small cell lung cancer.